One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Advances in cancer research dissemination through the pandemic and beyond
A.Desai1I.M.Subbiah2V.Subbiah234
Circulating tumor DNA in patients with metastatic prostate cancer treated with abiraterone acetate
Y.LoriotK.Fizazi
IgE blockade in the management of eosinophil-associated recalcitrant pruritus due to medical tumor therapy
R.Gutzmer1V.Sibaud2J.C.Hassel3
Small cell lung cancer: a slightly less orphan disease after immunotherapy
J.Remon1†M.Aldea2†B.Besse23D.Planchard2M.Reck4G.Giaccone5J.-C.Soria236
The systemic treatment of recurrent ovarian cancer revisited
T.Baert12A.Ferrero3J.Sehouli4D.M.O'Donnell5A.González-MartÃn6F.Joly7J.van der Velden8P.Blecharz9D.S.P.Tan1011D.Querleu12N.Colombo1314A.du Bois1†J.A.Ledermann15â€
Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial
A.Jayaram1A.Wingate1D.Wetterskog1G.Wheeler1C.N.Sternberg2R.Jones3A.Berruti4F.Lefresne5M.Lahaye5S.Thomas6M.Gormley6F.Meacham7K.Garg7L.P.Lim7A.S.Merseburger8B.Tombal9D.Ricci6G.Attard1
IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies
D.M.Barrios1†G.S.Phillips1†A.N.Geisler1S.R.Trelles1A.Markova12S.J.Noor12E.A.Quigley12H.C.Haliasos12A.P.Moy23A.M.Schram45J.Bromberg45S.A.Funt45M.H.Voss45A.Drilon45M.D.Hellmann45E.A.Comen45S.Narala6A.B.Patel6…M.E.Lacouture12
Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial
A.Bardia1W.A.Messersmith2E.A.Kio3J.D.Berlin4L.Vahdat5†G.A.Masters6R.Moroose7A.D.Santin8K.Kalinsky9‡V.Picozzi10J.O'Shaughnessy11J.E.Gray12T.Komiya13J.M.Lang14J.C.Chang15A.Starodub16D.M.Goldenberg17§R.M.Sharkey17…A.J.Ocean5
Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I
K.N.Moore1A.M.Oza2N.Colombo34A.Oaknin5G.Scambia6D.Lorusso7G.E.Konecny8S.Banerjee9C.G.Murphy10J.L.Tanyi11H.Hirte12J.A.Konner13P.C.Lim14M.Prasad-Hayes15B.J.Monk16P.Pautier17J.Wang18A.Berkenblit18…M.J.Birrer20
Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma
R.V.Rawson12345†C.Adhikari12345†C.Bierman6†S.N.Lo1E.Shklovskaya17E.A.Rozeman6A.M.Menzies1289A.C.J.van Akkooi6K.F.Shannon1234M.Gonzalez1A.D.Guminski189M.T.Tetzlaff1011J.R.Stretch12349H.Eriksson1213J.V.van Thienen6M.W.Wouters614J.B.A.G.Haanen6W.M.C.Klop6…R.A.Scolyer12345‡
Prospective evaluation of dietary and lifestyle pattern indices with risk of colorectal cancer in a cohort of younger women
Y.Yue1J.Hur1Y.Cao234F.K.Tabung156M.Wang789K.Wu1M.Song17910X.Zhang9Y.Liu911J.A.Meyerhardt12K.Ng12S.A.Smith-Warner17†W.C.Willett179†E.Giovannucci179â€
Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium
P.Grivas1†A.R.Khaki133†T.M.Wise-Draper2†B.French3†C.Hennessy3C.-Y.Hsu3Y.Shyr3X.Li4T.K.Choueiri5C.A.Painter6S.Peters7B.I.Rini3M.A.Thompson8S.Mishra3D.R.Rivera9J.D.Acoba10M.Z.Abidi11Z.Bakouny5…GdL.Lopes65â€
Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines
A.Vogel1E.Martinelli2ESMO Guidelines Committee
Complete pathological and serological response to immunotherapy in a patient with MMR-deficient early rectal cancer
L.S.Tarpgaard1P.V.Andersen2N.Øgaard34C.Demuth34C.L.Andersen34P.Pfeiffer15
PET-2-guided escalated BEACOPP for advanced nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the randomized German Hodgkin Study Group HD18 study
D.A.Eichenauer12†S.Kreissl12†I.Bühnen12C.Baues23C.Kobe24L.van Heek24H.Goergen12M.Fuchs12S.Hartmann5B.von Tresckow126A.Engert12P.Borchmann12
Artificial increase of uracilemia during fluoropyrimidine treatment can lead to DPD deficiency misinterpretation
F.Thomas12M.Maillard12M.Launay3C.Tron4M.-C.Etienne-Grimaldi5E.Gautier-Veyret67V.Haufroid89N.Pallet10B.Royer11C.Narjoz10A.Schmitt1213Groupe de Pharmacologie Clinique Oncologique (GPCO-UNICANCER)
Novel drugs, familiar interactions: ciprofloxacin may increase exposure to the RET inhibitor pralsetinib
F.CitarellaM.RussanoA.GallettiB.VincenziG.ToniniD.Santini
NTRK fusion in soft tissue sarcomas harboring MDM2/CDK4 amplification: three case reports
M.Brahmi12A.Dufresne1B.Verret3F.Tirode2J.Y.Blay12
Is impaired response to PD-1 blockers of high serum PD-1 patients related to immune complexes?
E.Daveri1E.Luison2V.Vallacchi1B.Vergani3B.E.Leone3M.C.Garassino4M.Figini2†L.Rivoltini1â€
Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer
V.Subbiah1T.Shen23M.Tetzlaff4A.Weissferdt4L.A.Byers5T.Cascone5A.Behrang6F.Meric-Bernstam1B.H.M.Mooers27S.M.Rothenberg8†K.Ebata8J.Wu23
Corrigendum to ‘VP1-2021: Efficacy of everolimus in patients with HR+/HER2- high risk early stage breast cancer’: Annals of Oncology 2021;32:574-575
T.Bachelot1F.Dalenc2S.Chabaud3P.Cottu4D.Allouache5E.Brain6J.-P.Jacquin7J.Grenier8L.Venat Bouvet9M.Brunt10M.Campone11F.Del Piano12M.Debled13A.-C.Hardy Bessard14S.Giacchetti15J.Bliss16J.-L.Canon17J.Lemonnier18…F.André20
Corrigendum to ‘Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’: [Annals of Oncology Volume 31, Issue 6, June 2020, Pages 697-712]
M.Heuser1Y.Ofran23N.Boissel45S.Brunet Mauri67C.Craddock8J.Janssen9A.Wierzbowska1011C.Buske12ESMO Guidelines Committee
